CD42b Monoclonal Antibody (HIP1), eBioscience™, Invitrogen™

Description

• Description: The HIP1 monoclonal antibody reacts with the human CD42b molecule, a 135 kDa transmembrane protein also known as platelet gpIb
• Applications Reported: The HIP1 antibody has been reported for use in flow cytometric analysis, in vitro blocking of human CD42b, immunoblotting (WB), and immunohistochemical staining
• (Please use Functional Grade purified HIP1, cat
• 16-0429, in functional assays.)
• Applications Tested: The HIP1 antibody has been tested by flow cytometric analysis of human platelets and can be used less than or equal to 1 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibodies be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• CD42b is a platelet activation marker involved in the process of coagulation as an aggregating factor
• It interacts with extracellular matrix as well as with adhesion molecules
• CD42b expression and activation seems to be regulated by VEGF and PDGF
• CD42b composes together with GPIb beta, GPIX and GPV the GPIb-IX-V receptor complex critical in the process of platelet-rich thrombus formation by tethering the platelet to a thrombogenic surface
• CD42b binds to von Willebrand factor (VWF) exposed at a site of vascular injury, as well as to thrombin, coagulation factors XI and XII, high molecular wight kininogen, TSP-1, integrin Mac-1 and P-selectin
• The extracellular domain of CD42b by its interactions also contributes to metastasis
• Further, CD42b antigen is expressed on platelets and on megakaryocytes in bone marrow
• Several polymorphisms and mutations have been described in the CD42b, some of which are the cause of Bernard-Soulier syndromes and platelet-type von Willebrand disease.